Precision BioSciences, Inc. (NasdaqCM: DTIL)
Health Care · Biotechnology · US
$6.43
+2.88% today · +12.8% 1Y
Precision BioSciences, Inc. (NasdaqCM: DTIL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $177.48M and employs 67 people.
Over the last twelve months the share price has gained 12.8%, trading between 3.53 and 9.62.
Tweenvest scores Precision BioSciences, Inc. across four factors: quality 50/100, value 63/100. Its strongest factor is value.
DTIL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $177.48M
- Revenue (TTM)
- $45.05M
- P/E
- —
- EPS
- -2.59
- Dividend yield
- —
- Beta (5Y)
- 1.28
- 52-week high
- $9.62
- 52-week low
- $3.53
- Avg volume (3M)
- —
- Shares outstanding
- 27.60M
- Employees
- 67
- Next earnings
- —
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
- ISIN
- US74019P2074
- Founded
- 2006
- Listed since
- Mar 28, 2019
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Nkarta, Inc.NasdaqGS: NKTX | $184.43M | $2.22 | -13.79% |
| Canton Strategic Holdings, Inc.NasdaqCM: CNTN | $179.28M | $2.08 | -7.56% |
| Satellos Bioscience Inc.TSX: MSCL | $178.75M | CA$10.42 | -13.24% |
| SinoMab BioScience LimitedSEHK: 3681 | $178.47M | HK$1.01 | +1.00% |
| Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.SEHK: 2566 | $176.80M | HK$5.78 | +1.49% |
| Pacific Edge LimitedNZSE: PEB | $174.22M | NZ$0.25 | -10.71% |
| OBI Pharma, Inc.TPEX: 4174 | $173.48M | NT$42.00 | +29.43% |
| Dx & Vx Co., Ltd.KOSDAQ: A180400 | $172.85M | ₩2,365.00 | -0.84% |
Figures last refreshed Oct 4, 2026.